دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation
Bassem I. Yamout, Shanthi Viswanathan , Joanna Laurson-Doube and Dilraj Sokhi
doi : 10.1177/13524585231205970
Volume 30 Issue 1, January 2024
Deciphering prognostic indicators in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: An integrative review of demographic and laboratory factors
Ruo-Yi Guo* , Wen-Ya Wang* , Jing-Ying Huang, Zhen Jia, Ya-Fei Sun and Bin Li
Re-thinking race and geography in multiple sclerosis
Daniel Ontaneda and Lilyana Amezcua
MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes
Edgar Carnero Contentti and Dean M Wingerchuk
MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No
Romain Marignier and Bruce AC Cree
MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Commentary
Brian G Weinshenker
A multicenter pilot study evaluating simplified central vein assessment for the diagnosis of multiple sclerosis
Lynn Daboul, Carly M O’Donnell, Moein Amin , Paulo Rodrigues, John Derbyshire, Christina Azevedo , Amit Bar-Or, Eduardo Caverzasi , Peter A Calabresi , Bruce AC Cree , Leorah Freeman, Roland G Henry, Erin E Longbrake, Jiwon Oh, Nico Papinutto, Daniel Pelletier, Vesna Prchkovska, Praneeta Raza, Marc Ramos, Rohini D Samudralwar, Matthew K Schindler, Elias S Sotirchos , Nancy L Sicotte, Andrew J Solomon, Russell T Shinohara, Daniel S Reich , Pascal Sati and Daniel Ontaneda
Serum macrophage migration inhibitory factor levels predict brain atrophy in people with primary progressive multiple sclerosis
Dimitrios C Ladakis* , Maria I Reyes-Mantilla*, Sachin P Gadani , Jackson W Mace , Susana C Dominguez-Penuela, Mayaa J Appiah , Matthew D Smith, Pavan Bhargava , Robert J Fox , Shiv Saidha and Peter A Calabresi
Disease progression in the first 5 years of treatment in multiple sclerosis: Predictive value of early brain and lesion volume changes
Rozemarijn M Mattiesing , Eline Kramer , Eva MM Strijbis , Iman Brouwer , Ronald A van Schijndel , Giordano Gentile , Marco Battaglini, Nicola De Stefano , Bernard MJ Uitdehaag, Frederik Barkhof , Hugo Vrenken* and Menno M Schoonheim
Odour discrimination and identification as a biomarker of long-term disability worsening in multiple sclerosis
Klaus Berek* , Harald Hegen*, Michael Auer, Robert Barket , Franziska Di Pauli, Jakob Hocher, Nik Krajnc , Anne Zinganell, Florian Deisenhammer , Thomas Berger and Gabriel Bsteh
A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis
Ruth Dobson , David Holden, Nicola Vickaryous, Jonathan Bestwick, Katila George, Tatiana Sayali, Lucia Bianchi, Mohammad Wafa, Julian Gold and Gavin Giovannoni
Effectiveness of a blended booster programme for the long-term outcome of cognitive behavioural therapy for MS-related fatigue: A randomized controlled trial
Marieke de Gier , Heleen Beckerman , Jos WR Twisk, Hans Knoop and Vincent de Groot
The disease-modifying therapy utilisation and cost trend for multiple sclerosis in Australia between 2013 and 2022
Ting Zhao, Bruce V Taylor, Julie A Campbell and Andrew J Palmer
Stretching is not essential for managing MS spasticity: A randomized controlled trial
Cinda L Hugos, Sandra K Joos, Suzanne E Perumean-Chaney, Gary R Cutter and Michelle H Cameron
A wearable device perspective on the standard definitions of disability progression in multiple sclerosis
Gloria Dalla Costa , Carlos Nos, Ana Zabalza , Mathias Buron , Melinda Magyari, Finn Sellebjerg, Ana Isabel Guerrero, Lucia Roselli, Maria Libera La Porta, Matteo Martinis, Raquel Bailon, Spyridon Kontaxis, Estela Laporta, Esther Garcia, Florian B Pokorny, Bj?rn W Schuller, Amos Folarin, Callum Stewart, Letizia Leocani , Srinivasan Vairavan, Nicholas Cummins, Richard Dobson, Matthew Hotopf, Vaibhav Narayan, Xavier Montalban, Per Soelberg Sorensen and Giancarlo Comi; on behalf of the RADAR-CNS consortium
Using instrumental variables to correct for bias in real-world cohort studies of the effects of disease-modifying treatment in MS
Nils I?rgen Koch-Henriksen , Lau Caspar Thygesen, Per Soelberg S?rensen and Melinda Magyari
The Finger Dexterity Test: Validation study of a smartphone-based manual dexterity assessment
Delphine Van Laethem* , Stijn Denissen* , Lars Costers, Annabel Descamps, Johan Baijot , Ann Van Remoortel, Annick Van Merhaegen-Wieleman, Marie B D’hooghe, Miguel D’Haeseleer , Dirk Smeets, Diana M Sima, Jeroen Van Schependom and Guy Nagels
Recurrence of severe symptomatic late-onset neutropenia on ocrelizumab
Ysoline Beigneux , Celine Louapre, Kevin Bihan, Thomas Roux , Raphael de Paz, Catherine Lubetzki and Elisabeth Maillart
Managing patients with late-onset neutropenia during treatment with ocrelizumab
Sarah L Wright and Alan J Thompson
